Home - Invivoscribe

Products & Clinical Lab Services

Invivoscribe

PRODUCTS & CLINICAL LAB SERVICES

Cat #: 40850310
BCR/ABL b2a2 RNA Dilution Set
Invivoscribe’s BCR/ABL b2a2 RNA Dilution Set consists of RNA that has been extracted from established BCR/ABL b2a2 positive and BCR/ABL negati...
View Product
Cat #: 40850210
BCR/ABL b3a2 RNA Dilution Set
Invivoscribe’s BCR/ABL b3a2 RNA Dilution Set consists of RNA that has been extracted from established BCR/ABL b3a2 positive and BCR/ABL negati...
View Product
Cat #: 40850110
BCR/ABL e1a2 RNA Dilution Set
Invivoscribe’s BCR/ABL e1a2 RNA Dilution Set consists of RNA that has been extracted from established BCR/ABL e1a2 positive and BCR/ABL negati...
View Product
Cat #: 23100041
BCR/ABL t(9;22) Mix 1b – HEX for ABI Fluorescence Detection
BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...
View Product
Cat #: 23100051
BCR/ABL t(9;22) Mix 2b – HEX for ABI Fluorescence Detection
BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...
View Product
Cat #: 23100061
BCR/ABL t(9;22) Mix 2c – HEX for ABI Fluorescence Detection
BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...
View Product
Cat #: 23100071
BCR/ABL t(9;22) Mix 3b – 6FAM for ABI Fluorescence Detection
BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...
View Product
Cat #: 23100081
BCR/ABL t(9;22) Mix 3c – 6FAM for ABI Fluorescence Detection
BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...
View Product
Cat #: 23100101
BCR/ABL t(9;22) Mix 3d – 6FAM for ABI Fluorescence Detection
BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...
View Product
Cat #: 13100031
BCR/ABL t(9;22) Translocation Assay for ABI Fluorescence Detection
BACKGROUND BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromos...
View Product
Cat #: 13110011
PML/RARα Translocation Assay for ABI Fluorescence Detection
Three PML/RARα translocation patterns have been identified in samples with acute myelogenous leukemia (AML): type A is the short (S-form); the breakp...
View Product

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing